Az IMI (Innovative Medicines Initiative) szervezete és gyógyszerkutatási projektjei

Az IMI Az EU és az EFPIA (European Federation of Pharmaceutical Industries and Associations) közös szervezete, amely 2 milliárd euro támogatást nyújt számos projektje révén akadémiai és gyógyszeripari kutatás-fejlesztések számára.

Betekintésül közöljük (fordítás nélkül) az IMI jelenleg folyamatban lévő 40 projektjét új kutatás-fejlesztési tématerületeket illetően.

Forrás, további információ:

• ABIRISK Anti-Biopharmaceutical Immunization: Prediction and Analysis of Clinical Relevance to Minimize the Risk
• BioVacSafe Biomarkers for Enhanced Vaccine Immunosafety
• BTCure Be The Cure
• CHEM21 Chemical manufacturing methods for the 21st century pharmaceutical industries
• COMBACTE Combatting Bacterial Resistance in Europe
• COMPACT Collaboration on the optimisation of macromolecular pharmaceutical access to cellular targets
• DDMoRe Drug Disease Model Resources
• DIRECT Diabetes research on patient stratification
• EHR4CR Electronic Health Records Systems for Clinical Research
• ELF European Lead Factory
• EMIF European Medical Information Framework
• EMTRAIN European Medicines Research Training Network
• eTOX Integrating bioinformatics and chemoinformatics approaches for the development of Expert systems allowing the in silico prediction of toxicities
• eTRIKS Delivering European Translational Information & Knowledge Management Services
• EU-AIMS European Autism Interventions - a Multicentre Study for Developing New Medications
• Eu2P European programme in Pharmacovigilance and Pharmacoepidemiology
• EUPATI European Patients' Academy on Therapeutic Innovation
• EUROPAIN Understanding chronic pain and improving its treatment
• IMIDIA Improving beta-cell function and identification of diagnostic biomarkers For treatment monitoring in diabetes
• K4DD Kinetics for Drug Discovery
• MARCAR Biomarkers and molecular tumour classification for non-genotoxic carcinogenesis
• MIP-DILI Mechanism-Based Integrated Systems for the Prediction of Drug-Induced Liver Injury
• NEWMEDS Novel methods leading to new medications in depression and schizophrenia
• Onco Track Methods for systematic next generation oncology biomarker development
• Open PHACTS The Open Pharmacological Concepts Triple Store
• ORBITO Oral biopharmaceutics tools
• Pharma-Cog Prediction of cognitive properties of new drug candidates for neurodegenerative diseases in early clinical development
• Pharmatrain Pharmaceutical Medicine Training Programme
• Predect New models for preclinical evaluation of drug efficacy in common solid tumours
• PreDiCT-TB Model-based preclinical development of anti-tuberculosis drug combinations
• PRO-active Physical Activity as a Crucial Patient Reported Outcome in COPD
• PROTECT Pharmacoepidemiological research on outcomes of therapeutics by a European consortium
• Quic-Concept Quantative imaging in cancer:connecting cellular process with therapy
• RAPP-ID Development of rapid point-of-care test platforms for infectious diseases
• SAFE-T Safer and Faster Evidence-based Translation
• SafeSciMET European Modular Education and Training Programme in Safety Sciences for Medicines
• STEMBANCC Stem cells for biological assays of novel drugs and predictive toxicology
• SUMMIT Surrogate markers for micro- and macro-vascular hard endpoints for innovative diabetes tools
• TRANSLOCATION Molecular basis of the bacterial cell wall permeability
• U-BIOPRED Unbiased biomarkers for the prediction of respiratory disease outcomes